Medtronic reports first quarter fiscal 2025 financial results

Product innovation driving growth across diversified health tech portfolio, including automated insulin delivery, transcatheter aortic valve replacement, pulsed field cardiac ablation, pain stimulation, and deep brain stimulation galway, ireland , aug. 20, 2024 /prnewswire/ -- medtronic plc (nyse: mdt) today announced financial results for its first quarter (q1) of fiscal year 2025 (fy25), which ended july 26, 2024. key highlights revenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as reported and 5.3% organic gaap diluted earnings per share (eps) of $0.80; non-gaap diluted eps of $1.23 company increases fy25 organic revenue growth and eps guidance multiple franchises delivering, with growth acceleration in cardiac ablation solutions and neuromodulation and continued strength in spine, structural heart, and diabetes financial results medtronic reported q1 worldwide revenue of $7.915 billion and adjusted revenue of $8.004 billion, an increase of 2.8% as reported and 5.3% on an organic basis.
MDT Ratings Summary
MDT Quant Ranking